Status:
COMPLETED
Efficacy of Re-challenge With Immune-Checkpoints Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients: a Retrospective Observational Study
Lead Sponsor:
University Hospital, Grenoble
Collaborating Sponsors:
Bristol-Myers Squibb
Conditions:
Non Small Cell Lung Cancer
Eligibility:
All Genders
Brief Summary
This is a multicentre, retrospective, national observational study aiming to describe clinical outcomes of advanced NSCLC patients that performed an ICP re-challenge during their history of disease. T...
Detailed Description
Immune checkpoint inhibitors (ICP), including nivolumab, pembrolizumab and atezolizumab, are currently approved by EMA (European Medicines Agency) and ANSM (National Agency for the Safety of Medicines...
Eligibility Criteria
Inclusion
- Diagnosis of NSCLC
- Advanced disease (stage III-IV) according to the TNM 7th /8th edition classification at the beginning of first ICP
- Patients must have received at least two lines of ICP during their history of disease
- Patients with EGFR mutation and/or ALK translocation must have received all specific target agents regularly reimbursed (during the reporting period) prior to the first PCI
Exclusion
- • Opposition form signed by the living patient or opposition clearly indicated in the deceased patient's medical records
Key Trial Info
Start Date :
January 22 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 15 2019
Estimated Enrollment :
144 Patients enrolled
Trial Details
Trial ID
NCT04069663
Start Date
January 22 2019
End Date
October 15 2019
Last Update
March 30 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hosipital, Grenoble
La Tronche, Isère, France, 38700